Dyne Therapeutics Investor Conference Presentations
Dyne Therapeutics, Inc. (NASDAQ: DYN), a company dedicated to improving the lives of individuals with genetically driven neuromuscular diseases, has unveiled its plans for a series of presentations at notable investor conferences. These conferences are pivotal moments for the company as they offer a platform to showcase their innovative approaches in the realm of therapeutic solutions.
Upcoming Presentation Schedule
Guggenheim Healthcare Innovation Conference
Firstly, Dyne will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference. This fireside chat is set to take place on a Monday at 10:00 a.m. ET. Attendees can expect insights into Dyne's latest advancements and strategic directions within the healthcare sphere.
Stifel Healthcare Conference
Following this, on Tuesday, Dyne has a scheduled fireside chat at the Stifel 2025 Healthcare Conference, beginning at 9:20 a.m. ET. This event will further highlight the company's commitment to innovation in therapeutic solutions for neuromuscular conditions.
Jefferies Global Healthcare Conference
Later in the month, Dyne will take the stage at the Jefferies Global Healthcare Conference. This presentation is crucial for sharing further developments and updates on their ongoing clinical projects.
Annual Evercore Healthcare Conference
Finally, Dyne is lined up for the 8th Annual Evercore Healthcare Conference on December 2nd at 9:35 a.m. ET. This event represents yet another opportunity for Dyne to connect with investors and share insights.
Live Webcast Details
For those unable to attend these conferences, Dyne Therapeutics will provide live webcasts of each presentation accessible through the Investors & Media section of their official website. Furthermore, a replay of each presentation will be available for 90 days, allowing broader access to the insights shared at these events.
About Dyne Therapeutics
Dyne Therapeutics has a clear and focused mission: delivering functional improvements for individuals living with genetically driven neuromuscular diseases. The company is actively developing therapeutics that address underlying causes by targeting muscle functionality and the central nervous system. Currently, Dyne is advancing clinical programs aimed at treating myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), in addition to preclinical programs focusing on facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
Company Contacts
Investor Relations
If you have any inquiries, please reach out to Mia Tobias at ir@dyne-tx.com or call 781-317-0353.
Media Inquiries
For media-related questions, contact Stacy Nartker at snartker@dyne-tx.com or call 781-317-1938.
Frequently Asked Questions
What is Dyne Therapeutics focused on?
Dyne Therapeutics is dedicated to developing treatments for genetically driven neuromuscular diseases.
When will Dyne present at investor conferences?
Dyne will present at various conferences, including Guggenheim, Stifel, Jefferies, and Evercore, between November and December 2025.
How can I watch the presentations?
Live webcasts of the presentations will be available on the Dyne Therapeutics website, with replays accessible for 90 days.
What diseases is Dyne Therapeutics working to treat?
Dyne is focused on conditions such as myotonic dystrophy type 1 and Duchenne muscular dystrophy, among others.
Who should I contact for investor relations?
For investor relations, contact Mia Tobias at ir@dyne-tx.com.
